Supplementary table

Table i: Post-hoc analysis of 200 patents from each group matched for gender, body mass index and acquisition window.

		Group 1 (QDS+)	Group 2 (AIDR)	Group 3 (AIDR3D and SUREexposure)	P
N		200	200	200	-
Male		44.5%	44.5%	44.5%	<0.001
Age (years)		58 (56, 59)	57 (56, 59)	59 (57, 60)	0.565
Heart rate (/min)		59 (58, 61)	59 (57, 60)	58 (57, 59)	0.479
Body mass index (kg/m^2)		28 (27, 29)	28 (28, 29)	28 (27, 29)	0.912
Acquisition window (30-80% vs 70-80%)		28 / 172	28 / 172	28 / 172	<0.001
Scan range (mm)		128	128	128	<0.001
Contrast (mL)		55 (54, 56)	54 (53, 54)	53 (52, 54)	0.064
Tube voltage (kV)	100	39%	43%	69%	
	120	58%	53%	31%	<0.001
	135	3%	4%	0%	
Tube current (mA)	100 kV	538 (530, 547)	447 (441, 453)	331 (307, 355)	<0.001
	120 kV	536 (531, 541)	426 (421, 430)	397 (362, 431)	<0.001
Subjective image quality		1.3 (1.2, 1.4)	1.1 (1.1, 1.2) *	1.1 (1.1, 1.2) *	<0.001
Aorta attenuation (HU)		430 (415, 443)	423 (411, 436)	533 (517, 549) * §	<0.001
Liver attenuation (HU)		65 (62, 67)	62 (60, 64)	60 (58, 62) *	0.01
IVS attenuation (HU)		88 (85, 92)	85 (83, 88)	88 (85, 90)	0.23
Image noise aorta (HU)		31 (30, 32)	31 (30, 32)	40 (39, 41) * §	<0.001
Image noise liver (HU)		39 (38, 41)	38 (37, 40)	39 (38, 40)	0.534
Image noise IVS (HU)		34 (32, 35)	32 (31, 33) *	37 (36, 38) * §	<0.001
Contrast-to-noise ratio		12 (12, 13)	12 (12, 13)	12 (12, 13)	0.747
Contrast-to-myocardium ratio		12 (11, 12)	12 (11, 12)	11 (11, 12)	0.823
DLP (mGy.cm)		261 (246, 276)	211 (199, 223) *	141 (129, 153) * §	<0.001

Mean (95% confidence interval) or percentage (%). (IVS, intraventricular septum; DLP, dose length product; HU, Hounsfield units)

* P<0.05 compared to Group 1, § P<0.05 compared to Group 2